Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

Press releases published on May 22, 2026

NBA All-Star Paul George Joins FlexiSpot as Brand Partner to Champion Movement, Balance, and Everyday Performance
Indonesia’s Pet Industry Sees Skyrocketing Growth as Pipper Standard® Launches Its 'Pet Healthy' Product Line
Zenapet Highlights Growing Focus on Mobility Support for Elderly Dogs
AFLE and SCCG Management Announce Strategic Partnership Ahead of Inaugural Season
Calidi Biotherapeutics Provides Required NYSE American Disclosure
Keolis MHI Celebrates International Day of Families with Special 'Work-Family Balance' Wellbeing Webinar
GlycoPulse Claims Evaluated: Most Advanced Blood Sugar Support Ingredients for Healthy Glucose Management by Glyco Pulse
Liquid Youth™ Joins Miami Swim Week® The Shows 2026 as Official Collagen Wellness Partner
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
XRSPACE and Riversoft Debut AI Avatars That Drive Travel Bookings — Live at TTE 2026
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
SCYNEXIS Announces One-for-Eight Reverse Stock Split
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
NANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars
XTL Announces Receipt of Staff Delist Determination from Nasdaq
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Alternative Medicine Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.